Oseltamivir Phosphate

Catalog No.S2597

For research use only.

Oseltamivir Phosphate is a potent and selective inhibitor of the neuraminidase that is essential for replication of influenza A and B viruses, used to prevent influenza.

Oseltamivir Phosphate  Chemical Structure

CAS No. 204255-11-8

Selleck's Oseltamivir Phosphate has been cited by 5 Publications

1 Customer Review

Purity & Quality Control

Choose Selective Neuraminidase Inhibitors

Biological Activity

Description Oseltamivir Phosphate is a potent and selective inhibitor of the neuraminidase that is essential for replication of influenza A and B viruses, used to prevent influenza.
Targets
Neuraminidase [1]
In vitro

Oseltamivir Phosphate, anti-Neu1 antibodies, and matrix metalloproteinase-9-specific inhibitor blocks Neu1 activity associated with EGF-stimulated TNBC MDA-MB-231 cells[2]. Oseltamivir slows the spread of influenza (flu) virus between cells in the body by stopping the virus from chemically cutting ties with its host cell.

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDCK cells NF;kXpJHfW6ldHnvckBie3OjeR?= MoHTN|YhcA>? MVXBcpRqcW6obIXlcppiKGGldHn2bZR6KGGpYXnud5QhcW6obIXlcppiKEFidnnyeZMhUDOQMjDpcoZm[3SnZDDpckBOTEONIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yhfmm{dYOtbY5lfWOnZDDjfZRweGG2aHnjJIVn\mWldDDh[pRmeiB|NjDodpMtKEmFNUC9NU4yKM7:TR?= MYWyNlM1OTl2Mx?=
In vivo Oseltamivir Phosphate monotherapy may be the effective treatment therapy for TNBC(Triple-negative breast cancers)[2]. It is efficacious in treating infections caused by H5N1 and H9N2 influenza viruses in mice[3]. After dosing, the prodrug (Oseltamivir phosphate) is readily absorbed from the gastrointestinal tract and rapidly converted into the active metabolite, OC. In all patient groups, OC has high bioavailability and is systemically distributed to infection sites at concentrations sufficient to inhibit a range of influenza virus neuraminidases[4].

Protocol (from reference)

Cell Research:[2]
  • Cell lines: MDA-MB-231 cells/MCF-7 cells
  • Concentrations: 500, 600, 700, 800 μg/mL
  • Incubation Time: 24, 48, and 72 h 
  • Method: Cells are incubated in 96-well plates (5,000 cells/well) and allowed to adhere for 24 hours in 1× DMEM media containing 10% FCS. The media are replaced with fresh DMEM media containing 5% FCS with or without various concentrations of tamoxifen or OP for indicated time periods. Cell viability is tested using WST-1 cell proliferation assay.
Animal Research:[2]
  • Animal Models: RAGxCγ double mutant mouse
  • Dosages: 30 or 50 mg/kg
  • Administration: i.p.

Solubility (25°C)

In vitro

DMSO 4 mg/mL warmed
(9.74 mM)
Water Insoluble
Ethanol Insoluble

Chemical Information

Molecular Weight 410.4
Formula

C16H28N2O4.H3PO4

CAS No. 204255-11-8
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCC(CC)OC1C=C(CC(C1NC(=O)C)N)C(=O)OCC.OP(=O)(O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05012189 Recruiting Drug: Oseltamivir|Drug: Baloxavir Influenza|Influenza Human|Influenza -Like Illness Insight Therapeutics LLC|Brown University|Case Western Reserve University|Genentech Inc. August 6 2021 Phase 4
NCT04516915 Recruiting Drug: IMU-838|Drug: Oseltamivir Covid 19 University Hospitals Coventry and Warwickshire NHS Trust|Immunic AG|University of Warwick|MODEPHARMA June 15 2020 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Oseltamivir Phosphate | Oseltamivir Phosphate supplier | purchase Oseltamivir Phosphate | Oseltamivir Phosphate cost | Oseltamivir Phosphate manufacturer | order Oseltamivir Phosphate | Oseltamivir Phosphate distributor